The new review appraises the evidence behind seven serious harms linked to GLP-1 receptor agonists, including where uncertainty remains and what it means for clinicians.
Recap by typeshit. Post by @journalofinternalmedicine on Instagram.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Exercise advice aimed at people on GLP-1 drugs, covering how to approach training while on the medication. Generic tips, so tap through for the specifics.
The eye clinic says most people on GLP-1 weight loss drugs don't need extra eye checks, but any vision changes are worth noticing.
Loading…